Lexicon Pharmaceuticals Competitors and Similar CompaniesClear all
Lexicon Pharmaceuticals's competitors and similar companies include ACADIA Pharmaceuticals, MannKind Corporation, Ajinomoto Bio-Pharma Services and CRISPR Therapeutics.
 Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. |  ACADIA Pharmaceuticals ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders. |  MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. |  Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO). |  CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases. | |
Founding Date | Founding Date 1995 | Founding Date 1993 | Founding Date 1991 | Founding Date 1998 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | Locations San Diego, US HQ Princeton, US | Locations Westlake Village, US HQ Danbury, US | Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP | Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US |
Employees | Employees 20216% increase | Employees 513 | Employees 39513% increase | Employees 68610% decrease | Employees 393 |
Valuation ($) | Valuation ($) 737.4 m | Valuation ($) 2.4 b | Valuation ($) 1.9 b | Valuation ($) N/A | Valuation ($) 4.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $49.8m (FY, 2025) | Revenue (est.) $1.1b (FY, 2025) | Revenue (est.) $349m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $3.5m (FY, 2025) |
Cost of goods | Cost of goods $274k (FY, 2025) | Cost of goods $89m (FY, 2025) | Cost of goods $26.8m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $49.5m (FY, 2025) | Gross profit $982.5m (FY, 2025) | Gross profit $322.2m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($50.3m) (FY, 2025) | Net income $391m (FY, 2025) | Net income $5.9m (FY, 2025) | Net income N/A | Net income ($581.6m) (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products 1 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 244.7m | Total funding raised $ 770.8m | Total funding raised $ 200m | Total funding raised $ 3.5m | Total funding raised $ 127m |
For sources of this data, please see the company profile
View Company Profiles
ACADIA Pharmaceuticals
HQ
San Diego, US
Employees
513
ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders.
View companyMannKind Corporation
HQ
Westlake Village, US
Employees
395↑ 13% increase
MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.
View companyAjinomoto Bio-Pharma Services
HQ
San Diego, US
Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO).
View companyCRISPR Therapeutics
HQ
Zug, CH
Employees
393
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
View company